NBIX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $67,228,668.36

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$132.00

▼ -0.54 (-0.41%)

As of 04/19/2024 01:00 AM ET

Days: 30 | 90 | 365

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Eric Benevich	Insider	Sell	19,818	$133.36	$2,642,928.48	40,778
3/21/2024	Ingrid Delaet	Insider	Sell	5,000	$145.06	$725,300.00	7,507
3/14/2024	Eric Benevich	Insider	Sell	75,000	$139.38	$10,453,500.00	40,778
3/14/2024	George J. Morrow	Director	Sell	40,000	$139.42	$5,576,800.00
3/11/2024	Ingrid Delaet	Insider	Sell	200	$140.00	$28,000.00	7,507
3/11/2024	Richard F. Pops	Director	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Ingrid Delaet	Insider	Sell	1,800	$140.03	$252,054.00	7,507
3/8/2024	Richard F. Pops	Director	Sell	1,700	$140.05	$238,085.00	29,512
2/29/2024	Ingrid Delaet	Insider	Sell	273	$135.51	$36,994.23	7,507
2/27/2024	Leslie V. Norwalk	Director	Sell	8,000	$135.67	$1,085,360.00
2/20/2024	Richard F. Pops	Director	Sell	15,000	$132.47	$1,987,050.00	29,512
2/13/2024	Eiry Roberts	Insider	Sell	1,114	$132.96	$148,117.44	23,716
2/13/2024	Kevin Charles Gorman	CEO	Sell	2,832	$133.02	$376,712.64	514,596
2/13/2024	Matt Abernethy	CFO	Sell	1,352	$132.85	$179,613.20	31,528
2/8/2024	David W. Boyer	Insider	Sell	1,328	$135.41	$179,824.48	4,895
2/8/2024	Kevin Charles Gorman	CEO	Sell	2,274	$134.15	$305,057.10	506,962
2/8/2024	Matt Abernethy	CFO	Sell	980	$134.21	$131,525.80	30,314
2/6/2024	David W. Boyer	Insider	Sell	456	$141.96	$64,733.76	4,894
2/6/2024	Kevin Charles Gorman	CEO	Sell	3,040	$142.18	$432,227.20	504,919
2/6/2024	Matt Abernethy	CFO	Sell	1,280	$142.19	$182,003.20	29,434
1/31/2024	Eiry Roberts	Insider	Sell	1,457	$140.79	$205,131.03	20,832
1/31/2024	Kevin Charles Gorman	CEO	Sell	2,707	$140.69	$380,847.83	502,188
1/31/2024	Matt Abernethy	CFO	Sell	1,283	$140.72	$180,543.76	28,284
1/22/2024	Darin Lippoldt	Insider	Sell	10,000	$139.86	$1,398,600.00	35,882
1/8/2024	Kevin Charles Gorman	CEO	Sell	105,835	$132.44	$14,016,787.40	499,754
1/2/2024	Kyle Gano	Insider	Sell	75,000	$131.47	$9,860,250.00	130,250
1/2/2024	William H. Rastetter	Director	Sell	11,044	$131.47	$1,451,954.68	51,741
12/22/2023	Eiry Roberts	Insider	Sell	10,000	$126.74	$1,267,400.00	19,521
12/12/2023	Eiry Roberts	Insider	Sell	13,925	$120.30	$1,675,177.50	29,521
12/8/2023	Eiry Roberts	Insider	Sell	300	$120.10	$36,030.00	29,521
12/6/2023	Darin Lippoldt	Insider	Sell	20,830	$119.86	$2,496,683.80	35,882
12/1/2023	Gary A. Lyons	Director	Sell	5,000	$116.77	$583,850.00	203,697
11/29/2023	Jude Onyia	Insider	Sell	2,331	$113.57	$264,731.67	11,732
11/27/2023	Darin Lippoldt	Insider	Sell	10,919	$112.27	$1,225,876.13	35,882
10/2/2023	David W. Boyer	Insider	Sell	1,437	$112.68	$161,921.16	4,894
9/12/2023	Gary A. Lyons	Director	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Gary A. Lyons	Director	Sell	5,000	$110.06	$550,300.00	203,697
9/1/2023	Julie Cooke	Insider	Sell	824	$110.93	$91,406.32	17,263
8/30/2023	David W. Boyer	Insider	Sell	2,733	$107.60	$294,070.80	3,460
8/28/2023	Ingrid Delaet	Insider	Sell	1,431	$107.52	$153,861.12	5,931
8/21/2023	Jude Onyia	Insider	Sell	3,198	$107.37	$343,369.26	9,638
8/21/2023	Kevin Charles Gorman	CEO	Sell	9,328	$107.40	$1,001,827.20	499,754
8/21/2023	Matt Abernethy	CFO	Sell	2,132	$107.39	$228,955.48	27,131
5/1/2023	Julie Cooke	Insider	Sell	11,397	$103.89	$1,184,034.33	16,169
5/1/2023	William H. Rastetter	Director	Sell	4,300	$101.43	$436,149.00	42,785
4/24/2023	Eiry Roberts	Insider	Sell	14,400	$103.48	$1,490,112.00	26,644
4/21/2023	William H. Rastetter	Director	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	William H. Rastetter	Director	Sell	903	$105.00	$94,815.00	34,729
2/23/2023	Neurocrine Biosciences Inc	Major Shareholder	Buy	4,395,588	$8.88	$39,032,821.44	8,575,316
2/8/2023	Eric Benevich	Insider	Sell	980	$104.12	$102,037.60	34,381
2/8/2023	Kevin Charles Gorman	CEO	Sell	2,274	$104.30	$237,178.20	491,365
2/7/2023	Matt Abernethy	CFO	Sell	26,328	$102.40	$2,695,987.20	24,333
2/6/2023	Eric Benevich	Insider	Sell	1,280	$105.63	$135,206.40	17,879
2/6/2023	Kevin Charles Gorman	CEO	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Eiry Roberts	Insider	Sell	1,457	$109.99	$160,255.43	26,171
1/31/2023	Kevin Charles Gorman	CEO	Sell	2,707	$110.08	$297,986.56	465,278
1/31/2023	Matt Abernethy	CFO	Sell	1,283	$109.98	$141,104.34	21,357
1/6/2023	Eric Benevich	Insider	Sell	400	$125.00	$50,000.00	15,643
1/3/2023	Stephen A. Sherwin	Director	Sell	30,000	$118.86	$3,565,800.00	25,055
11/30/2022	Eric Benevich	Insider	Sell	50,000	$125.90	$6,295,000.00	15,643
11/10/2022	Eric Benevich	Insider	Sell	100	$125.36	$12,536.00	15,643
11/8/2022	Eric Benevich	Insider	Sell	24,593	$125.33	$3,082,240.69	15,643
11/3/2022	Darin Lippoldt	Insider	Sell	4,518	$125.02	$564,840.36	29,234
11/1/2022	Darin Lippoldt	Insider	Sell	10,000	$120.09	$1,200,900.00	29,234
10/31/2022	Gary A. Lyons	Director	Sell	15,000	$114.76	$1,721,400.00	203,697
10/27/2022	Darin Lippoldt	Insider	Sell	4,923	$115.04	$566,341.92	29,234
10/17/2022	Eric Benevich	Insider	Sell	4,960	$110.82	$549,667.20	15,643
10/4/2022	Gary A. Lyons	Director	Sell	5,000	$110.54	$552,700.00	203,697
10/3/2022	David W. Boyer	Insider	Sell	1,437	$106.59	$153,169.83	4,214
8/12/2022	Malcolm Lloyd-Smith	Insider	Sell	21,533	$105.95	$2,281,421.35	18,888
6/27/2022	Julie Cooke	Insider	Sell	754	$100.00	$75,400.00	16,918
5/9/2022	Richard F. Pops	Director	Sell	15,000	$76.30	$1,144,500.00	29,512
4/25/2022	Gary A. Lyons	Director	Sell	15,000	$92.76	$1,391,400.00	208,697
4/1/2022	William H. Rastetter	Director	Sell	10,728	$94.93	$1,018,409.04	34,022
3/22/2022	Darin Lippoldt	Insider	Sell	8,455	$95.05	$803,647.75
3/18/2022	Darin Lippoldt	Insider	Sell	300	$95.00	$28,500.00
2/7/2022	David W. Boyer	Insider	Sell	240	$81.07	$19,456.80
2/7/2022	Kevin Charles Gorman	CEO	Sell	8,710	$80.82	$703,942.20
2/7/2022	Matt Abernethy	CFO	Sell	3,310	$80.79	$267,414.90
1/24/2022	Stephen A. Sherwin	Director	Sell	15,000	$74.43	$1,116,450.00
1/10/2022	Eiry Roberts	Insider	Sell	2,632	$74.50	$196,084.00
1/5/2022	Kyle Gano	Insider	Sell	28,266	$85.50	$2,416,743.00
12/1/2021	Matt Abernethy	CFO	Sell	1,645	$82.59	$135,860.55
10/7/2021	Dimitri E. Grigoriadis	Insider	Sell	8,000	$104.81	$838,480.00
10/7/2021	Gary A. Lyons	Director	Sell	5,000	$105.06	$525,300.00
10/4/2021	Julie Cooke	Insider	Sell	987	$101.73	$100,407.51
8/16/2021	Eric Benevich	Insider	Sell	5,628	$89.62	$504,381.36
7/27/2021	Malcolm Lloyd-Smith	Insider	Sell	16,709	$93.80	$1,567,304.20	15,801
6/10/2021	Gary A. Lyons	Director	Sell	10,000	$100.27	$1,002,700.00

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

92.59% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/19/2024	First Trust Direct Indexing L.P.	4,130	$0.57M	0.0%	+29.2%	0.004%
4/19/2024	Norden Group LLC	2,848	$0.39M	0.0%	N/A	0.003%
4/19/2024	State of Alaska Department of Revenue	10,795	$1.49M	0.0%	+1.7%	0.011%
4/19/2024	Sumitomo Mitsui Trust Holdings Inc.	252,565	$34.83M	0.0%	+3.5%	0.254%
4/19/2024	Handelsinvest Investeringsforvaltning	2,241	$0.31M	0.1%	-34.2%	0.002%
4/18/2024	State of Michigan Retirement System	24,481	$3.38M	0.0%	+3.8%	0.025%
4/18/2024	Allspring Global Investments Holdings LLC	506,666	$69.88M	0.1%	+23.5%	0.509%
4/17/2024	Hennion & Walsh Asset Management Inc.	6,805	$0.94M	0.1%	+14.3%	0.007%
4/16/2024	Toth Financial Advisory Corp	5,500	$0.76M	0.1%	+34.6%	0.006%
4/16/2024	Sendero Wealth Management LLC	19,563	$2.70M	0.5%	-1.3%	0.020%
4/16/2024	Chesley Taft & Associates LLC	7,500	$1.03M	0.1%	N/A	0.008%
4/16/2024	Wealth Enhancement Advisory Services LLC	4,744	$0.65M	0.0%	+48.5%	0.005%
4/15/2024	Thompson Investment Management Inc.	7,625	$1.05M	0.2%	-1.0%	0.008%
4/12/2024	Washington Capital Management Inc.	4,000	$0.55M	0.4%	-15.8%	0.004%
4/11/2024	Clarus Wealth Advisors	1,490	$0.21M	0.1%	-19.1%	0.001%
4/11/2024	Tealwood Asset Management Inc.	12,008	$1.66M	0.7%	-2.0%	0.012%
4/10/2024	Park Avenue Securities LLC	9,570	$1.32M	0.0%	+1.1%	0.010%
4/10/2024	Banque Cantonale Vaudoise	1,186	$0.16M	0.0%	+197.2%	0.001%
4/9/2024	Woodstock Corp	7,509	$1.04M	0.1%	-26.2%	0.008%
4/9/2024	Rise Advisors LLC	352	$49K	0.0%	+576.9%	0.000%
4/9/2024	Mather Group LLC.	198	$26K	0.0%	N/A	0.000%
4/5/2024	First Hawaiian Bank	5,163	$0.71M	0.0%	-2.0%	0.005%
4/5/2024	Juncture Wealth Strategies LLC	8,425	$1.16M	0.5%	+4.2%	0.008%
4/5/2024	GAMMA Investing LLC	1,158	$0.16M	0.0%	+36.6%	0.001%
4/5/2024	Los Angeles Capital Management LLC	245,381	$33.84M	0.1%	-73.3%	0.247%
4/5/2024	CWM LLC	4,664	$0.64M	0.0%	+60.7%	0.005%
3/29/2024	Kapitalo Investimentos Ltda	503	$66K	0.0%	N/A	0.001%
3/26/2024	HighPoint Advisor Group LLC	2,510	$0.35M	0.0%	N/A	0.003%
3/22/2024	PNC Financial Services Group Inc.	3,247	$0.43M	0.0%	-11.0%	0.003%
3/21/2024	Healthcare of Ontario Pension Plan Trust Fund	71,000	$9.36M	0.0%	N/A	0.071%
3/11/2024	Vanguard Group Inc.	9,710,328	$1.28B	0.0%	+1.6%	9.758%
3/5/2024	Fisher Asset Management LLC	60,227	$7.94M	0.0%	-2.6%	0.061%
3/5/2024	Wellington Management Group LLP	1,199,542	$158.05M	0.0%	-9.7%	1.205%
3/1/2024	Goldman Sachs Group Inc.	691,632	$91.13M	0.0%	-12.1%	0.695%
2/28/2024	American International Group Inc.	133,543	$17.60M	0.1%	-3.5%	0.134%
2/26/2024	Teachers Retirement System of The State of Kentucky	31,280	$4.12M	0.0%	-4.9%	0.031%
2/26/2024	Perceptive Advisors LLC	270,794	$35.68M	0.8%	+70.1%	0.272%
2/21/2024	American Trust	2,680	$0.35M	0.0%	-12.1%	0.003%
2/20/2024	Quarry LP	300	$40K	0.0%	-84.2%	0.000%
2/20/2024	Aurora Investment Counsel	13,726	$1.81M	1.1%	+2.6%	0.014%
2/16/2024	DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main	18,511	$2.44M	0.0%	-9.6%	0.019%
2/16/2024	Public Employees Retirement System of Ohio	44,960	$5.92M	0.0%	+13.8%	0.045%
2/15/2024	Mercer Global Advisors Inc. ADV	5,292	$0.70M	0.0%	+29.9%	0.005%
2/15/2024	Dodge & Cox	1,259,744	$165.98M	0.1%	+489.8%	1.266%
2/15/2024	Virtus Fund Advisers LLC	687	$91K	0.6%	+70.9%	0.001%
2/15/2024	Virtus ETF Advisers LLC	2,688	$0.35M	0.2%	-16.7%	0.003%
2/15/2024	Legal & General Group Plc	576,888	$76.01M	0.0%	+28.7%	0.580%
2/15/2024	Andra AP fonden	72,800	$9.59M	0.5%	+33.3%	0.073%
2/15/2024	Perpetual Ltd	6,786	$0.89M	0.0%	N/A	0.007%
2/15/2024	Vanguard Group Inc.	9,710,328	$1.28B	0.0%	+1.6%	9.758%
2/15/2024	Voloridge Investment Management LLC	22,009	$2.90M	0.0%	N/A	0.022%
2/15/2024	Voya Investment Management LLC	134,746	$17.75M	0.0%	-24.5%	0.135%
2/15/2024	Vident Advisory LLC	2,535	$0.33M	0.0%	-5.7%	0.003%
2/15/2024	Weiss Multi Strategy Advisers LLC	11,480	$1.51M	0.0%	N/A	0.012%
2/15/2024	Nuveen Asset Management LLC	360,523	$47.50M	0.0%	-1.2%	0.362%
2/15/2024	Price T Rowe Associates Inc. MD	1,476,949	$194.60M	0.0%	+25.2%	1.484%
2/15/2024	Profund Advisors LLC	15,271	$2.01M	0.1%	-4.6%	0.015%
2/15/2024	Parkman Healthcare Partners LLC	140,116	$18.46M	2.6%	+67.1%	0.141%
2/15/2024	Gotham Asset Management LLC	5,538	$0.73M	0.0%	+9.5%	0.006%
2/15/2024	Healthcare of Ontario Pension Plan Trust Fund	71,000	$9.36M	0.0%	N/A	0.071%
2/15/2024	Baird Financial Group Inc.	25,585	$3.37M	0.0%	-3.2%	0.026%
2/15/2024	Bayesian Capital Management LP	8,653	$1.14M	0.1%	N/A	0.009%
2/15/2024	Brevan Howard Capital Management LP	5,506	$0.73M	0.0%	+181.6%	0.006%
2/15/2024	Bridgefront Capital LLC	2,453	$0.32M	0.2%	N/A	0.002%
2/14/2024	Pathstone Holdings LLC	6,368	$0.84M	0.0%	N/A	0.006%
2/14/2024	Braidwell LP	715,209	$94.24M	3.5%	-26.1%	0.719%
2/14/2024	Point72 Asset Management L.P.	1,391,970	$183.41M	0.4%	-46.0%	1.399%
2/14/2024	Creative Planning	9,714	$1.28M	0.0%	+17.6%	0.010%
2/14/2024	Cubist Systematic Strategies LLC	27,843	$3.67M	0.0%	-75.3%	0.028%
2/14/2024	Avidity Partners Management LP	658,000	$86.70M	3.2%	+0.9%	0.661%
2/14/2024	First Financial Bankshares Inc	15,802	$2.08M	0.1%	N/A	0.016%
2/14/2024	Ethic Inc.	4,456	$0.59M	0.0%	+22.2%	0.004%
2/14/2024	Bridgewater Associates LP	23,505	$3.10M	0.0%	-57.3%	0.024%
2/14/2024	Superstring Capital Management LP	29,346	$3.87M	2.8%	N/A	0.029%
2/14/2024	Bellevue Group AG	2,430,500	$320.24M	4.9%	-5.9%	2.442%
2/14/2024	Balyasny Asset Management L.P.	219,826	$28.96M	0.1%	-58.4%	0.221%
2/14/2024	Cresset Asset Management LLC	3,553	$0.47M	0.0%	+2.9%	0.004%
2/14/2024	State of Tennessee Treasury Department	46,992	$6.19M	0.0%	-10.0%	0.047%
2/14/2024	Verition Fund Management LLC	1,897	$0.25M	0.0%	-95.3%	0.002%
2/14/2024	Sei Investments Co.	115,958	$15.28M	0.0%	+28.1%	0.117%
2/14/2024	Shell Asset Management Co.	2,933	$0.39M	0.0%	-18.8%	0.003%
2/14/2024	Ossiam	5,376	$0.71M	0.0%	+12.9%	0.005%
2/14/2024	Scout Investments Inc.	261,618	$34.47M	0.9%	-28.5%	0.263%
2/14/2024	Seven Eight Capital LP	7,215	$0.95M	0.1%	N/A	0.007%
2/14/2024	Vestal Point Capital LP	800,000	$105.41M	11.2%	N/A	0.804%
2/14/2024	Sectoral Asset Management Inc.	4,445	$0.59M	0.3%	+10.2%	0.004%
2/14/2024	Schroder Investment Management Group	75,535	$9.95M	0.0%	+31.1%	0.076%
2/14/2024	Prudential PLC	19,931	$2.63M	0.0%	-3.0%	0.020%
2/13/2024	Vinva Investment Management Ltd	4,801	$0.63M	0.0%	+15.7%	0.005%
2/13/2024	Envestnet Asset Management Inc.	199,586	$26.30M	0.0%	+3.5%	0.203%
2/13/2024	Stephens Inc. AR	6,888	$0.91M	0.0%	+16.1%	0.007%
2/13/2024	Northern Trust Corp	807,281	$106.37M	0.0%	-4.3%	0.822%
2/13/2024	American International Group Inc.	133,543	$17.60M	0.1%	-3.5%	0.136%
2/13/2024	Cibc World Markets Corp	2,720	$0.36M	0.0%	N/A	0.003%
2/13/2024	Public Employees Retirement Association of Colorado	11,684	$1.54M	0.0%	+67.3%	0.012%
2/13/2024	1832 Asset Management L.P.	41,000	$5.40M	0.0%	N/A	0.042%
2/13/2024	Oppenheimer & Co. Inc.	17,169	$2.26M	0.0%	+1.5%	0.017%
2/13/2024	Crossmark Global Holdings Inc.	8,056	$1.06M	0.0%	-5.7%	0.008%
2/13/2024	Tower Research Capital LLC TRC	14,153	$1.87M	0.0%	+36.8%	0.014%
2/13/2024	Armistice Capital LLC	1,048,000	$138.08M	1.9%	-13.8%	1.067%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $132.00

$130.13

$133.65

50 Day Range

MA: $136.15

$130.40

$143.74

52 Week Range

Now: $132.00

$89.04

$148.37

Volume

556,052 shs

Average Volume

843,646 shs

Market Capitalization

$13.14 billion

P/E Ratio

54.55

Dividend Yield

N/A

Beta

0.25

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Malcolm Lloyd-Smith (Insider)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
David W Boyer (Insider)
George J Morrow (Director)
Leslie V Norwalk (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
Allspring Global Investments Holdings LLC — 0.51%
Sumitomo Mitsui Trust Holdings Inc. — 0.25%
Los Angeles Capital Management LLC — 0.25%
Portman Square Capital LLP — 0.00%
State of Michigan Retirement System — 0.02%
Sendero Wealth Management LLC — 0.02%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
Los Angeles Capital Management LLC
Woodstock Corp
Handelsinvest Investeringsforvaltning
Washington Capital Management Inc.
Clarus Wealth Advisors
Sendero Wealth Management LLC
Tealwood Asset Management Inc.
First Hawaiian Bank
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Malcolm Lloyd-Smith (Insider)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
Allspring Global Investments Holdings LLC
Sumitomo Mitsui Trust Holdings Inc.
Chesley Taft & Associates LLC
Norden Group LLC
Curated Wealth Partners LLC
CWM LLC
Wealth Enhancement Advisory Services LLC
Toth Financial Advisory Corp